Usman Baber News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Objective To assess the absolute treatment effects of intravascular imaging guided versus angiography guided percutaneous coronary intervention in patients with coronary artery disease, considering their baseline risk. Design Systematic review and meta-analysis. Data sources PubMed/Medline, Embase, and Cochrane Library databases up to 31 August 2023. Study selection Randomized controlled trials comparing intravascular imaging (intravascular ultrasonography or optical coherence tomography) guided versus coronary angiography guided percutaneous coronary intervention in adults with coronary arter...

Analysis of TWILIGHT trial shines light on Effect of Therapies following percutaneous coronary intervention 

After percutaneous coronary intervention, ticagrelor alone or with aspirin are equally effective in preventing repeat revascularization at one year in a post-hoc TWILIGHT analysis.

Operators have been in love with aspirin for a long time, but all signs point to it being time to move on, says Mladen Vidovich.

New insights from the TWILIGHT trial showed that ticagrelor monotherapy after three months of ticagrelor plus aspirin was associated with similar rates of recurrent coronary revascularization, major adverse cardiac and cerebrovascular events (MACCE) and a lower risk of net adverse clinical events (NACE) compared with duel antiplatelet therapy (DAPT).